Corporate strategies adopted by Indian Pharmaceutical Industry for restructuring

  • Venkata Ramana Murthy Kolapalli
  • Vijaya Ratna Jayanti


The Indian pharmaceutical industry has developed rapidly over the last few decades. Before TRIPS, the Indian regulatory system recognized only process patents. The Indian Pharmaceutical companies were engaged in the development of new processes for manufacturing drugs. They mainly concentrated on the domestic markets and unregulated markets. The Indian companies focussed very little on Research & Development (R&D). Even large pharmaceutical companies showed little interest on innovation and R & D. They mostly depended on imitation and reverse engineering of the patented products. But after TRIPS, product patent was reintroduced and the companies spent their expenditure on R&D, synthesis of new chemical entities (NEC), and on modification of already existing entities to develop new formulations and development of generics to obtain regulatory approvals for marketing already patent expired drugs. The multinational companies have turned to contract manufacturing and research services (CRAMS), marketing alliances, collaborative research and clinical trials to save time and cost.  The main advantage of the Indian firms lies with their capability for low cost of production, and in their highly skilled technical labour. The manufacturing cost is less in India when compared to the US and the European countries. The Indian Pharmaceutical industry developed different types of strategies in order to survive and expand in the international pharmaceutical sector which involve collaborative strategies, business strategies, and overall corporate growth strategies.

Keywords: TRIPS (Trade Related aspects of Intellectual Property Rights), Indian Pharmaceutical industry, corporate strategies, business strategies, R&D, CRAMS (Contract Research and Manufacturing services).


Download data is not yet available.


1. Indian Pharmaceutical Industry. IBEF [Internet]. India Brand Equity Foundation; 2018 [Cited 2018 Oct 02]. Available from:
2. Lalitha N. Indian pharmaceutical industry in WTO regime: a SWOT analysis. Economic and political weekly. 2002 Aug; 24:3542-55
3. Ghai D. Patent protection and Indian pharmaceutical industry. International Journal of Pharmaceutical Sciences Review and Research. 2010 Feb 23; 3(2):43-8.
4. Lalitha N. Indian pharmaceutical industry in WTO regime: a SWOT analysis. Economic and political weekly. 2002 Aug; 24:3542-55.
5. Reddy CD, Gupta NV. Overview on contract research and manufacturing services (CRAMs) and its present status in India. Asian Journal of Pharmaceutical and Clinical Research. 2013; 6(2):33-7.
6. Rai RK. Battling with TRIPS: Emerging Firm Strategies of Indian Pharmaceutical Industry Post- TRIPS. Journal of Intellectual Property Rights. 2008; 13:301-17.
7. Kale D, Little S. From imitation to innovation: The evolution of R&D capabilities and learning processes in the Indian pharmaceutical industry. Technology Analysis & Strategic Management. 2007 Sep 01; 19(5):589-609.
8. Drabu S, Gupta A, Bhadauria A. Emerging trends in contract research industry in India. Contemporary clinical trials. 2010 Sep 01; 31(5):419-22.
9. “Elder Pharma, Enzymotec ink in- licensing deal” .The Economic Times [Internet]. 2007 Apr 25 [Cited 2018 Jan 02]. Available from:
Madhuri International Journal of Drug Regulatory Affairs. 2018; 6(4):33-41
e-ISSN: 2321-6794 [41]
10. “Pharma firms eye in-licensing opportunities”. Business standard [Internet]. 2013 Feb 05 [cited 2018 Jan 02]. Available from: /pharma-firms-eye-in-licensing-opportunities-107042601094_1.html.
11. “GSK and Ranbaxy expand R & D pact”. Business Standard [Internet]. 2013 Feb 26 [cited 2018 Jan 04]. Available from: /ranbaxy-gsk-expand-r-d-pact-107020701067_1.html.
12. “Torrent and AstraZeneca enter into R&D deal”. Business Standard [Internet]. 2013 Jan 19 [cited 2018 Jan 25]. Available from: /torrent-pharma-astrazeneca-in-r-d-deal-105022200003_1.html.
13. “Lupin US arm in Cefiximealliance”. Business Standard [Internet]. 2013 Feb 06 [cited 2018 Feb 10]. Available from: /lupin-us-arm-in-cefixime-alliance-105012801001 _1.html.
14. Nicholas to rake in $30m sales via 2 contract deals”. Business Standard [Internet]. 2013 Feb 06 [cited 2018 Feb 16]. Available from: /nicholas-to-rake-in-30m-sales-via-2-contract-deals-104110501077_1.html.
15. Bucklin LP, Sengupta S. Organizing successful co-marketing alliances. The Journal of Marketing. 1993 Apr; 1:32-46.
16. “Strides Acrolab signs two licensing and supply agreements with Pfizer”. IIFL [Internet]. 2010 May 14 [cited 2018 Mar 05]. Available from:
17. “Ranbaxy gets $4 million from Schwarz Pharma”. Business standard [Internet]. 2013 Feb 06 [cited 2018 May 06]. Available from: /ranbaxy-gets-4-million-from-schwarz-pharma-104062401033_1.html.
18. “Lupin, Novartis in marketing tie-up”. Business Standard [Internet]. 2013 Jan 20 [cited 2018 May 20]. Available from: _1.html. 19. “Dabur Pharma in deal with Abbott of US”. The Economic Times [Internet]. 2003 Oct 22 [cited 2018 Jun 10]. Available from: .cms.
20. Vyas V, Narayanan K, Ramanathan A. Determinants of mergers and acquisitions in Indian pharmaceutical industry. Eurasian Journal of Business and economics. 2012; 5(9):79-102.
21. “Merck, Sun Pharma enter JV for emerging markets”. Business Standard [Internet]. 2013 Jan 20 [cited 2018 July 01]. Available from: /merck-sun-pharma-enter-jv-for-emerging-markets-111041200083_1.html.
22. “Abbott Acquires India’s Piramal Health for $3.72 bn”. The Times of India [Internet]. 2010 May 22 [cited 2018 Aug 18]. Available from:
23. “Sun Pharma to acquire Ranbaxy in a US $4 billion landsmark transaction”. IIFL [Internet]. 2014 April 06 [cited 2018 Sep 15]. Available from:
24. “AIOCD AWACS” monthly report; 2018 Oct.
25. “National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers” [Internet]. 2014 [cited 2018 Sept 20]. Available from:
356 Views | 1994 Downloads
How to Cite
Chokkakula, B. M., V. R. Murthy Kolapalli, and V. Ratna Jayanti. “Corporate Strategies Adopted by Indian Pharmaceutical Industry for Restructuring”. International Journal of Drug Regulatory Affairs, Vol. 6, no. 4, Dec. 2018, pp. 33-41, doi:10.22270/ijdra.v6i4.282.